This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add RMD Stock to Your Portfolio Now
by Zacks Equity Research
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
Should You Retain Hologic Stock in Your Portfolio Now?
by Zacks Equity Research
HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns.
Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
by Zacks Equity Research
NEOG faces intense competition resulting from competitors' development of new technologies, which could affect the marketability and profitability of its products.
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
by Zacks Equity Research
According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.
Expanding Global Market, NuVasive Benefits to Aid GMED Stock
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
by Zacks Equity Research
LH launches new enhancements to Global Trial Connect to streamline site workflow.
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
by Zacks Equity Research
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.
Here's Why Haemonetics (HAE) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
National Vision Q3 Earnings Top Estimates, Revenues Lag, Stock Tumbles
by Zacks Equity Research
EYE's third-quarter 2024 results reflect ongoing strength in Managed Care, with growth in America's Best stores.
Wall Street Analysts Think Haemonetics (HAE) Could Surge 25.58%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Haemonetics (HAE) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
by Zacks Equity Research
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.
Compared to Estimates, Haemonetics (HAE) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Haemonetics (HAE) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 2.75% and 0.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Solventum Q3 Earnings Likely to Reflect Declining Volume Trend
by Zacks Equity Research
SOLV's Q3 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset sales decline.
Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings
by Zacks Equity Research
BAX's third-quarter results are likely to benefit from a positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
by Zacks Equity Research
Continued solid uptake of BD's products is expected to have driven fiscal fourth-quarter revenues.
Here's Why You Should Retain DGX Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HAE vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Here's Why You Should Retain ABT Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the Diagnostics and Nutrition business. Yet, unfavorable forex impacts are concerning.
Is GMED Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Globus Medical's synergistic merger with NuVasive and a cadence of product launches bring optimism to investors.
Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings?
by Zacks Equity Research
HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise.
Is Insulet Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.